- Home
- ATAT vs VRNA Comparison
ATAT vs VRNA Comparison
Compare ATAT & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAT
- VRNA
- Stock Information
- Founded
- ATAT 2013
- VRNA 2005
- Country
- ATAT China
- VRNA United Kingdom
- Employees
- ATAT N/A
- VRNA N/A
- Industry
- ATAT Hotels/Resorts
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- ATAT Consumer Discretionary
- VRNA Health Care
- Exchange
- ATAT Nasdaq
- VRNA Nasdaq
- Market Cap
- ATAT 3.7B
- VRNA 3.4B
- IPO Year
- ATAT 2022
- VRNA 2017
- Fundamental
- Price
- ATAT $25.85
- VRNA $51.89
- Analyst Decision
- ATAT Strong Buy
- VRNA Strong Buy
- Analyst Count
- ATAT 2
- VRNA 7
- Target Price
- ATAT $23.69
- VRNA $50.57
- AVG Volume (30 Days)
- ATAT 900.1K
- VRNA 1.4M
- Earning Date
- ATAT 11-19-2024
- VRNA 02-27-2025
- Dividend Yield
- ATAT 1.74%
- VRNA N/A
- EPS Growth
- ATAT 162.91
- VRNA N/A
- EPS
- ATAT 1.20
- VRNA N/A
- Revenue
- ATAT $950,764,843.00
- VRNA $5,624,000.00
- Revenue This Year
- ATAT $55.87
- VRNA N/A
- Revenue Next Year
- ATAT $25.40
- VRNA $550.30
- P/E Ratio
- ATAT $21.59
- VRNA N/A
- Revenue Growth
- ATAT 76.11
- VRNA 1127.95
- 52 Week Low
- ATAT $15.22
- VRNA $11.39
- 52 Week High
- ATAT $29.90
- VRNA $55.42
- Technical
- Relative Strength Index (RSI)
- ATAT 46.80
- VRNA 64.25
- Support Level
- ATAT $24.92
- VRNA $43.44
- Resistance Level
- ATAT $26.04
- VRNA $55.42
- Average True Range (ATR)
- ATAT 0.94
- VRNA 3.32
- MACD
- ATAT -0.14
- VRNA 0.40
- Stochastic Oscillator
- ATAT 26.56
- VRNA 70.52
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.